TVM Capital Healthcare has announced a USD 35 million investment in Boston Oncology Arabia, a bio-generic drugs manufacturer based in Saudi Arabia. Headquartered in Riyadh with a production facility in Sudair Industrial City, Boston Oncology Arabia focuses on locally developing and manufacturing high-quality therapeutics licensed from international standards.
The company plays a pivotal role in meeting Saudi Arabia’s increasing demand for specialty generics and biosimilars, aligning with the goals of Saudi Vision 2030 by enhancing local manufacturing capabilities and leveraging global licensing agreements.
TVM Capital Healthcare, known for its expertise in healthcare expansion and growth capital, will support Boston Oncology Arabia in expanding its manufacturing capabilities and accessing international markets. This partnership aims to bolster the company’s leadership in oncology and critical care therapeutics across the GCC and MENA region.
Abdullah Baaj, MD, PharmD, Founder & CEO of Boston Oncology Arabia, emphasized the strategic value of TVM Capital Healthcare’s investment in advancing their localization strategy and expanding market reach.
Orhan Osmansoy, Managing Partner at TVM Capital Healthcare, highlighted Boston Oncology Arabia’s pivotal role in Saudi Arabia’s pharmaceutical sector and the firm’s commitment to enhancing local production and healthcare accessibility.
Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, underscored the investment’s significance in promoting access to high-quality, locally manufactured generics and biosimilars in the Kingdom and beyond.
TVM Capital Healthcare, recognized as a pioneer in healthcare investment in Saudi Arabia and the wider region, continues to support healthcare growth initiatives globally, facilitating access to innovative healthcare solutions in emerging markets.
